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As proven earlier, in patients with tuberculosis (TB) the concentration of antituberculosis drugs like isoniazid and rifampi-
cin may differ depending on polymorphism of CYP2C19. The aim of the research was to determine the peculiarities of the 
pulmonary TB course and its outcome after the in-patient treatment depending on CYP2C19 genotype of the patients. The 
analysis of medical cards from 83 patients with the primary pulmonary tuberculosis at the end of the in-patient treatment 
in Odessa regional TB dispensary was conducted in 2012 with consideration of CYP2C19 genotype. At the beginning of the 
treatment the processes of disintegration were 3 times less in patients with *1/*1 genotype than in patients with *1/*2 
genotype (10.3% versus 31.8%; P<0.05; χ2=5.40), and 6.5 times less than in individuals with *2/*2 genotype (10.3% versus 
66.7%; P<0.05; χ2=7.94). At the end of the in-patient treatment the signs of pulmonary destruction were 6.5 times more 
common in individuals with *1/*1 genotype than in individuals with *1/*2 genotype (29.3 versus 4.5; Р<0.05; χ2=5.61). The 
signs of resorption and consolidation in the pulmonary tissue were observed in 74.1% of the patients with *1/*1 genotype, 
95.5% of the patients with *1/*2 genotype and 66.7% of the patients with *2/*2 genotype. There were no significant dif-
ferences between groups in relation to duration of the treatment and development of drug-resistance. Today, tuberculosis (TB) or “white plague” remains a major cause of death among in- fectious diseases in Ukraine. De- spite certain positive changes, for example, reducing the TB inciden- ce during the period of 2006-2011 from 83.2 to 67.2 per 100 000 of the population [5, 8], it is still a high level of multidrug-resistant tuberculosis – from 7 to 25% of the primary resistance to 75% of the secondary resistance, and it 
significantly reduces the efficien- cy of treatment [2, 7]. 
It is known that the efficien- cy of treatment of numerous disea- ses, the severity of their course and their outcome largely depend on the genetic characteristics of a person, for example from poly-morphism of genes of xenobiotics 
detoxification [9, 11]. Among the last there is an important gene of cytochrome P450 2C19 (CYP2C19), the expression of which is activa- ted by anti-TB antibiotic rifampi- cin [6]. On the other hand, rifampi- cin can be a substrate for CYP2C19 and polymorphism of its gene may affect the metabolism of rifampi- 
cin and consequently the effici- ency of TB treatment. In previous studies it has been shown that TB 
patients have higher frequency of the variant alleles (*2, *3) than heal- thy people do, and it is also noted that polymorphism of CYP2C19 ge- notype in TB patients associated with differences of rifampicin and isoniazid concentrations [1, 2]. So, the next step was to study the ef- 
ficiency of treatment of TB-pati- ents considering CYP2С19 geno-type. The aim of the research is to detect the peculiarities of the pul-monary TB course and the out-come after the in-patient treat- ment depending on CYP2C19 ge-notype of the patients.
Materials and Methods The analysis of medical cards from 83 patients with the prima-ry pulmonary tuberculosis at the end of the in-patient treatment in Odessa regional TB dispensary was 
conducted in 2012. Among the en- 
rolled patients 39 of them (47.0%) were women, others – 44 (53.0%) were men. The age varied from 18 
to 73 years old (average – 35.9 years 
old). All TB patients received the same standard therapy according to the Order of Ministry of Public 
Health No. 384 from 9.06.2006 re- gardless of CYP2C19 genotype [4]. 
We considered medical diagnosis at the beginning and at the end of in-patients treatment, including TB-form, characteristics of TB-le- sions, bacterial excretion, etc. 
At the beginning of the treat-ment provided CYP2C19 genoty- pe in TB-patients was detected. 
The DNA material was extracted from the blood of donors using a 
DNA sorbB kit (AmpliSens, Rus- sian Federation). CYP2C19 geno-type was detected with the help of the polymerase chain reaction 
(PCR) and endonuclease analysis 
according to J. A. Goldstein, J. Blais- 
dell, 2004 [10]. For PCR amplifica- tion of CYP2C19*2 and CYP2C19*3 alleles two pairs of relevant spe-
cific primers were used. PCR pro- ducts of CYP2C19*2 and CYP2C19*3 were exposed to the action of re-striction enzymes (restrictases) 
SmaI і BamH1, respectively. As the restriction was absent in the mu- 
tant alleles, PCR products avoid- ed digestion by the corresponding restrictase enzymes. Processing of the statistical data obtained was performed using Microsoft Excel and “Primer Biostatistica” pro-grammes.
Results and DiscussionIn accordance with the geno-type of CYP2C19 approximately 
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ers of the homozygous wild type of the gene *1/*1, 26.5% – carriers of the heterozygous genotype *1/*2, 
and finally, 3.6% – carriers of the variant (mutated) genotype – *2/*2. For convenience it is possible to attribute the persons with *1/*1 genotype to rapid metabolizers 
(RM), persons with *1/*2 geno- type to intermediate metabolizers (IM) and persons with *2/*2 ge- notype to slow metabolizers (SM).
At the beginning of the treat- ment in the in-patient department the destruction processes in lungs were observed approximately in 
one third of RM (37.9%), in half of IM and in all SM. Thus, one could see the processes of destruction in patients with *1/*1 genotype almost three times more often than in patients with *2/*2 genotype 
(Р<0.05; χ2=4.54 at a critical value here and after 3.84) (Table 1).
Approximately one third of RM and IM had a bilateral pulmona- ry TB, about 66.7% of SM had a bilateral process as well. The dis- seminative pulmonary TB was ob- served almost in one third of ge- notype *1/*1 carriers (29.3%), in two-third of genotype *2/*2 car-
riers and only in 13.6% individu-als with *1/*1 genotype. 
In the majority of RM and IM 
an infiltrative TB was observed, in addition in IM it was 1.5 times 
more often than in RM (86.4% ver- 
sus 58.6%, Р<0.05; χ2=5.49) (Fig. 1). 
A focal pulmonary TB was detec- 
ted only in 12.1% of RM and it was completely absent in IM and SM. 
Among the RM processes dis- integration and dissemination in 
lungs occurred in 10.3 and 29.3%, 
respectively (Table 1). At the same time among IM these processes were observed in 31.8% of the pa- tients, among SM – in 66.7% and 33.3%, respectively. Thus, among the patients with *1/*1 genotype the processes of disintegration were 3 times less than in the patients with *1/*2 genotype (P<0.05; χ2= =5.40), and 6.5 times less than in individuals with *2/*2 genotype 
(P<0.05; χ2=7.94). Meanwhile, the processes of the pulmonary tis-sues infiltration occurred more 
often in RM – 60.3%, almost twice as less in IM – 36.4% (P>0.05). On the contrary, the processes of 
infiltration were completely ab-
sent in SM (Р<0.05; χ2=4.25). 
At the beginning of the in-pa- tient treatment regardless of the genotype and according to the mic- roscopy approximately half of the patients with genotype *1/*1 and 
*1/*2 (46.6% and 50.0%, respec- tively) and two-thirds of the indi-viduals with genotype *2/*2 were 
smear-positive (Fig. 2). According to the cultural method the majo- 
rity of patients – 62.5% of RM, 
59.1% of IM and 66.7% of SM were smear-positive. The vast majori- ty of the patients with the geno-
type of RM, IM or SM belonged to I (primary pulmonary tuberculo- sis) or III category (smear-nega- 
tive primary tuberculosis) – 87.9%; 
95.5% and 100%, respectively. Thus, at the beginning of the treatment the patients with genotype *1/*1 had manifestations of disintegra- tion and destruction in pulmona- ry tissues more often than carri-ers of *1/*2 or *2/*2 genotype. Duration of the in-patient treat- ment was the longest in the indi- viduals with *1/*1 genotype – 
93.6±3.3 days. In the patients with *1/*2 or *2/*2 it was shorter – 
86.8±2.7 days or 86.5±7.8 days, respectively. 
Table 1
Characteristics of tuberculosis processes depending on CYP2C19 genotype
Characteristics  
of TB-processes
At the beginning of the treatment, (%) At the end of the in-patient treatment, (%)
*1/*1, n=58 *1/*2, n=22 *2/*2, n=3 *1/*1, n=58 *1/*2, n=22 *2/*2, n=3
Spreading
bilateral 23 (39.7) 7 (31.8) 2 (66.7) 23 (39.7) 6 (27.3) 2 (66.7)
unilateral 35 (60.3) 15 (68.2) 1 (33.3) 35 (60.3) 16 (72.7) 1 (33.3)
Destruction
yes 22 (37.9) 11 (50.0) 3* (100) 17 (29.3) 1*# (4.5) 1 (33.3)
no 36 (62.1) 11 (50.0) 0 41 (70.7) 21 (95.5) 2 (66.7)
Stage of the 
TB-process
infiltration 35 (60.3) 8 (36.4) 0* 6# (10.3) 1# (4.5) 1 (33,3)
disintegration 6 (10.3) 7* (31.8) 2* (66.7) 9 (15.5) 0*# 0
dissemination 17 (29.3) 7 (31.8) 1 (33.3) 0# 0# 0
resorption 0 0 0 43# (74.1) 21# (95.5) 2 (66.7) 
Category  
of patients
1 39 (67.2) 19 (86.4) 3 (100) 38 (65.5) 16 (72.7) 2 (66.7)
2 6 (10.3) 1 (4.5) 0 3 (5.2) 1 (4.5) 0
3 12 (20.7) 2 (9.1) 0 6 (10.3) 1 (4.5) 0
4 1 (1.7) 0 0 11# (19.0) 4# (18.2) 1 (33.3)
Multidrug 
resistance 1 (1.7) 0 0 11 (19.0) 4 (18.2) 1 (33.3)
Notes:  
1) # – Р<0.05 (in relation to the initial level of the corresponding group);  
2) * – Р<0.05 (in relation to the patients with *1/*1 genotype).
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At the end of the in-patient treatment the processes of de-
struction remained in 29.3% of 
RM and one-third of SM (Table 1). 
At the same time in IM the pro-cesses mentioned above were in 4.5%. Thus, the signs of pulmo- nary destruction were 6.5 times more in the individuals with *1/*1 genotype than in the individuals with *1/*2 genotype (Р<0.05; χ2= =5.61). In all groups as the result of the treatment provided there was reduction of the number of pa- tients with the symptoms of destruc- 
tion, particularly in IM (Р<0.05; 
χ2=11.46) (Table 2). Termination of destruction was observed in 27.3% of the persons with *1/*1 genotype, in two-thirds of *2/*2 
genotype carriers and in 90.9% of the individuals with *1/*2 ge- notype. Thus, conversion of the pul- monary destruction in IM occured 
3.3 times more often (P<0.05; χ2= 
=11.89) than in RM, and it took about 60 days on an average. 
At the end, as well as at the beginning of the in-patient treat-
ment, in majority of RM and IM (53.4% and 81.8%, respectively) 
infiltrative tuberculosis was ob- served (Fig. 1). Thus, at the end of 
the treatment provided an infiltra- tive TB occurred in IM 1.5 times 
more often than in RM (P<0.05; 
χ2=5.41). At the same time the two- third of SM had a disseminating form of pulmonary TB. 
As a result of the treatment 
conducted, the number of RM and 
IM with tuberculosis infiltration 
decreased by 5.6 times (P<0.05 χ2= 
=31.73) and by 8.1 times (P<0.05; 
χ2=6,84), respectively; further spreading (contamination) of TB 
in lungs stopped (P<0.05; χ2=19.92 
and χ2=8.32, respectively) (Table 1).
In IM at the end of the in-pa- tient treatment the further spread- ing (contamination) of TB in lungs was terminated, and the differen- 
ce was significant in relation to the baseline, as well as in relation 
to the RM stationary treatment ceas- ed phenomenon of disintegration, and the difference was statistical- 
ly significant in relation to the ba- 
seline (P<0.05; χ2=8.32) and RM 
(P<0.05; χ2=3.85). At the same time the signs of resorption and con- 
Fig. 1.  Forms of the pulmonary TB taken into consideration CYP2C19 genotype at the beginning (before)  
and at the end (after) of the in-patient treatment  
Note: *-Р<0.05 (in relation to the patients with *1/*1 genotype).
Fig. 2.  The number of patients with different CYP2C19 genotype that were 
smear- positive according to bacterioscopy (B+) or the culture 
method (C+) at the beginning (before) and at the end (after)  
of the in-patient treatment 
Note: * – Р<0.05 in relation to the initial level of the corresponding 
group.
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solidation in the pulmonary tissue 
were observed in 74.1% of RM, 
95.5% of IM (P<0.05; χ2=68.33 
and χ2=40.17, respectively) and in 66.7% of SM.
Regardless of the genotype the percentage of patients with bi- and unilateral TB-lesions of the lungs almost did not change during the in-patient treatment. During the treatment conducted the number of patients with genotype *1/*1, 
*1/*2 and *2/*2 belonging to cate- gory 4 increase up approximately 
equally – by 17.3% (P<0.05; χ2= 
=9.29), 18.2% (P<0.05; χ2=4.40) and 33.3% (P>0.05), respective-ly. The number of multidrug re-
sistant TB cases in the first and second groups was also almost 
the same – 19.0% and 18.2%, re-spectively.
According to bacterioscopy all 
SM and IM, as well as 98.3% of RM at the time of discharge from the hos- pital were smear-negative (Fig. 2). In addition, smear conversion was 
in 96.3% and 66.7% of SM and RM, respectively, and in 100% of IM. It took 58 days for conversion of 
positive smears for RM and IM and 47.5 days for SM, therefore, it was 
1.2 times faster than in RM (Р=0.020; 
СІ=1.91…20.49) (Table 2). 
According to the data of the culture method at the end of the in-patient treatment 40% of the individuals with *1/*1 and *1/*2 genotype, as well as one-third of the individuals with *2/*2 genotype remained smear-positive (Fig. 2). 
As a result of the treatment, the number of smear-positive patients with *1/*1 genotype decreased by 
almost 1.5 times (P<0.05; χ2=5.83). The smear conversion observed had 
almost the same speed in RM and 
IM – within 69 days (Table 2).The data obtained have pro- ven that at the beginning of treat- ment the signs of destruction, in- 
filtration and disintegration were more common in the patients with genotype CYP2C19*1/*1 than in patients with CYP2C19*1/*2 or 
CYP2C19*2/*2 genotypes. At the end of the in-patient treatment the processes of resorption and abor- tion of destruction were more of- ten associated with *1/*2 geno-
type. According to the prelimina- ry data the genotype – *1/*2 men- tioned below was associated with a high concentration of isoniazid and a slightly lower concentration of rifampicin in the blood during the treatment [8]. On the other hand, the patients with genoty- 
pes *1/*1 or *1/*2 had approxi-mately the same duration of the in-patient treatment and the per- centage of positive smears at the beginning and at the end of the treatment provided and the same number of the developed cases of drug-resistant tuberculosis. Un- 
fortunately, it was difficult to as-sess the impact of the presence of genotype*2/*2 on the tuber-culosis process due to the small number of such patients.CONCLUSIONS
1. At the beginning of the treat- ment the patients with genotype 
*1/*1 had manifestations of disin-tegration and destruction in pul- monary tissues more often than carriers of *1/*2 or *2/*2 genotype.
2. At the end of in-patient treat- ment the processes of resorption and abortion of destruction were more often associated with *1/*2 than *1/*1 genotype. 3. The patients with *1/*1 or 
*1/*2 genotypes had approxima- tely the same duration of the in-pa-tient treatment and the percent- age of positive smears at the be- ginning and at the end of the treat- ment provided and the same num- ber of the developed cases of drug- resistant tuberculosis. 
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НАСЛІДКИ ЛІКУВАННЯ ТУБЕРКУЛЬОЗУ ЛЕГЕНЬ ЗАЛЕЖНО ВІД ГЕНОТИПУ CYP2C19
П.Б.Антоненко, В.Й.Кресюн
Одеський національний медичний університет
Ключові слова: туберкульоз; CYP2C19; наслідки лікування
У попередніх дослідженнях було показано, що поліморфізм гена CYP2C19 у хворих на туберкульоз (ТБ) асоціював-
ся з відмінностями у концентраціях рифампіцину та ізоніазиду в крові хворих. Метою дослідження було визна-
чення особливостей перебігу та наслідків лікування туберкульозу легень на стаціонарному етапі в залежності 
від генотипу CYP2C19. Було проведено аналіз медичних карт 83 хворих на вперше діагностований туберкульоз 
легенів наприкінці стаціонарного лікування в Одеському обласному протитуберкульозному диспансері в 2012 р. 
з урахуванням генотипу CYP2C19. На початку лікування у хворих, які мали генотип *1/*1, процеси розпаду спо-
стерігались у 3 рази рідше, ніж у хворих з генотипом *1/*2 (10.3% проти 31.8%; P<0.05; χ2=5.40) і в 6,5 разів рідше, 
ніж у хворих з генотипом *2/*2 (10.3% versus 66.7%; P<0.05; χ2=7.94). Наприкінці стаціонарного лікування ознаки 
деструкції легеневої тканини спостерігались у 6.5 разів частіше за носіїв генотипу *1/*1, ніж у осіб з геноти-
пом *1/*2 (29.3 versus 4.5; Р<0.05; χ2=5.61). Ознаки розсмоктування і ущільнення легеневої тканини відзначались 
у 74.1% осіб з генотипом *1/*1, у 95.5% осіб з генотипом *1/*2 і 66.7% осіб з генотипом *2/*2. Вірогідна різниця 
між групами щодо тривалості стаціонарного лікування та розвитку хіміорезистентного туберкульозу була 
відсутня. 
ИСХОД ЛЕЧЕНИЯ ТУБЕРКУЛЕЗА ЛЕГКИХ В ЗАВИСИМОСТИ ОТ ГЕНОТИПА CYP2C19
П.Б.Антоненко, В.И.Кресюн
Одесский национальный медицинский университет
Ключевые слова: туберкулез; CYP2C19; исход лечения
В предыдущих исследованиях было продемонстрировано, что полиморфизм гена CYP2C19 у больных туберкулезом 
(ТБ) ассоциировался с отличиями концентраций рифампицина и изониазида в крови больных. Целью исследо-
вания было определение особенностей течения и исходов лечения туберкулеза легких на стационарном этапе 
в зависимости от генотипа CYP2C19. Был проведен анализ медицинских карт 83 больных с впервые диагно-
стированным туберкулезом легких при завершении стационарного лечения в Одесском областном противо-
туберкулезном диспансере в 2012 г. с учетом генотипа CYP2C19. В начале лечения у больных, имевших генотип 
*1/*1, процессы распада наблюдались в 3 раза реже, чем у больных с генотипом *1/*2 (10.3% против 31.8%; 
P<0.05; χ2=5.40) и в 6,5 раз реже, чем у больных с генотипом *2/*2 (10.3% против 66.7%; P<0.05; χ2=7.94). В конце 
стационарного лечения признаки деструкции легочной ткани наблюдались в 6.5 раз чаще у носителей геноти-
па *1/*1, чем у лиц с генотипом *1/*2 (29.3 против 4.5; Р<0.05; χ2=5.61). Признаки рассасывания и уплотнения 
легочной ткани отмечались у 74.1% пациентов с генотипом *1/*1, у 95.5% лиц с генотипом *1/*2 и 66.7% лиц с 
генотипом *2/*2. Достоверная разница между группами относительно длительности стационарного лечения 
и развития химиорезистентного туберкулеза отсутствовала. 
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